HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients
| Autor: | Karin Abbink, Petra LM Zusterzeel, Anneke J Geurts-Moespot, Antonius E van Herwaarden, Johanna MA Pijnenborg, Fred CGJ Sweep, Leon FAG Massuger |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Tumor Biology, Vol 40 (2018) |
| Druh dokumentu: | article |
| ISSN: | 1423-0380 10104283 |
| DOI: | 10.1177/1010428318757103 |
| Popis: | Objective: To date, biomarkers are not routinely used in endometrial cancer diagnosis, prognosis, and follow-up. The purpose of this study was to evaluate whether serum HE4 was related to clinicopathological risk factors and outcome. Second, the role of serum HE4 and CA125 was assessed as indicator for recurrent disease during follow-up. Methods: A total of 174 patients with endometrial cancer between 1999 and 2009 were selected for this retrospective study. Serum HE4 and CA125 were analyzed at primary diagnosis, during follow-up, and at the time of recurrence. Correlations with clinicopathological factors were studied by univariate and multivariate survival analyses. Lead time was calculated in order to determine which serum marker was elevated prior to clinical detection of recurrent disease. Results: Serum levels of HE4 and CA125 were significantly associated with high tumor grade, myometrial invasion, lymph node involvement, and advanced stage (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|